{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T04:05:23Z","timestamp":1791345923172,"version":"4.3.1"},"reference-count":264,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T00:00:00Z","timestamp":1794614400000},"content-version":"am","delay-in-days":378,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.blre.2025.101323","type":"journal-article","created":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T23:17:19Z","timestamp":1753485439000},"page":"101323","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Target practice: Opportunities for therapeutic intervention in CHIP and CCUS"],"prefix":"10.1016","volume":"74","author":[{"given":"Ayman","family":"Mohammad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Mascarenhas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bridget K.","family":"Marcellino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel I.","family":"Nathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.blre.2025.101323_bb0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejcb.2023.151340","article-title":"Clones of aging: when better fitness can be dangerous","volume":"102","author":"Marongiu","year":"2023","journal-title":"Eur J Cell Biol"},{"key":"10.1016\/j.blre.2025.101323_bb0010","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1038\/nm.3733","article-title":"Age-related mutations associated with clonal hematopoietic expansion and malignancies","volume":"20","author":"Xie","year":"2014","journal-title":"Nat Med"},{"key":"10.1016\/j.blre.2025.101323_bb0015","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2025.101323_bb0020","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.exphem.2019.11.008","article-title":"Inflammatory cytokines promote clonal hematopoiesis with specific mutations in ulcerative colitis patients","volume":"80","author":"Zhang","year":"2019","journal-title":"Exp Hematol"},{"key":"10.1016\/j.blre.2025.101323_bb0025","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2019.223305","article-title":"Clonal hematopoiesis in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis","volume":"105","author":"Arends","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2025.101323_bb0030","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1182\/blood.2021011320","article-title":"Clinical relevance of clonal hematopoiesis in persons aged \u226580 years","volume":"138","author":"Rossi","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101323_bb0035","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1126\/science.aag1381","article-title":"Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice","volume":"355","author":"Fuster","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.blre.2025.101323_bb0040","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1701719","article-title":"Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease","volume":"377","author":"Jaiswal","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2025.101323_bb0045","doi-asserted-by":"crossref","DOI":"10.1111\/acel.13366","article-title":"Clonal hematopoiesis associated with epigenetic aging and clinical outcomes","volume":"20","author":"Nachun","year":"2021","journal-title":"Aging Cell"},{"key":"10.1016\/j.blre.2025.101323_bb0050","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/j.stem.2024.05.010","article-title":"Selective advantage of mutant stem cells in human clonal hematopoiesis is associated with attenuated response to inflammation and aging","volume":"31","author":"Jakobsen","year":"2024","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.blre.2025.101323_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2023.107022","article-title":"Clonal hematopoiesis due to mosaic chromosomal alterations: impact on disease risk and mortality","volume":"126","author":"Hubbard","year":"2023","journal-title":"Leuk Res"},{"key":"10.1016\/j.blre.2025.101323_bb0060","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1038\/s41591-021-01411-9","article-title":"Combined landscape of single-nucleotide variants and copy number alterations in clonal hematopoiesis","volume":"27","author":"Saiki","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.blre.2025.101323_bb0065","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.yjmcc.2021.07.004","article-title":"Clonal hematopoiesis of indeterminate potential (CHIP): linking somatic mutations, hematopoiesis, chronic inflammation and cardiovascular disease","volume":"161","author":"Marnell","year":"2021","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.blre.2025.101323_bb0070","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1056\/NEJMoa1409405","article-title":"Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence","volume":"371","author":"Genovese","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2025.101323_bb0075","doi-asserted-by":"crossref","first-page":"12484","DOI":"10.1038\/ncomms12484","article-title":"Clonal haematopoiesis harbouring AML-associated mutations is ubiquitous in healthy adults","volume":"7","author":"Young","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.blre.2025.101323_bb0080","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.ajhg.2015.01.011","article-title":"Characterization of large structural genetic mosaicism in human autosomes","volume":"96","author":"Machiela","year":"2015","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.blre.2025.101323_bb0085","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/s41586-018-0321-x","article-title":"Insights into clonal haematopoiesis from 8,342 mosaic chromosomal alterations","volume":"559","author":"Loh","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.blre.2025.101323_bb0090","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/s41467-020-20565-7","article-title":"Interplay between chromosomal alterations and gene mutations shapes the evolutionary trajectory of clonal hematopoiesis","volume":"12","author":"Gao","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.blre.2025.101323_bb0095","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1038\/s41588-023-01553-1","article-title":"Mosaic chromosomal alterations in blood across ancestries using whole-genome sequencing","volume":"55","author":"Jakubek","year":"2023","journal-title":"Nat Genet"},{"key":"10.1016\/j.blre.2025.101323_bb0100","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1182\/blood-2017-01-763425","article-title":"Clinical significance of somatic mutation in unexplained blood cytopenia","volume":"129","author":"Malcovati","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101323_bb0105","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/bjh.18273","article-title":"Clinical implications and genetic features of clonal cytopenia of undetermined significance compared to lower-risk myelodysplastic syndrome","volume":"198","author":"Choi","year":"2022","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2025.101323_bb0110","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1182\/bloodadvances.2020003976","article-title":"Clinical, molecular, and prognostic comparisons between CCUS and lower-risk MDS: a study of 187 molecularly annotated patients","volume":"5","author":"Li","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2025.101323_bb0115","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1038\/s41375-024-02297-5","article-title":"Parallel genomic analysis from paired bone marrow and peripheral blood samples of 200 cytopenic patients","volume":"38","author":"Huber","year":"2024","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2025.101323_bb0120","first-page":"1161","article-title":"Mutational spectrum and dynamics of clonal hematopoiesis in anemia of older individuals","volume":"135","author":"van Zeventer","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101323_bb0125","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200310","article-title":"Prediction of risk for myeloid malignancy in clonal hematopoiesis","volume":"2","author":"Weeks","year":"2023","journal-title":"NEJM Evid"},{"key":"10.1016\/j.blre.2025.101323_bb0130","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1182\/blood.2024024756","article-title":"Risk prediction for clonal cytopenia: multicenter real-world evidence","volume":"144","author":"Xie","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101323_bb0135","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1038\/s41588-023-01472-1","article-title":"Multiparameter prediction of myeloid neoplasia risk","volume":"55","author":"Gu","year":"2023","journal-title":"Nat Genet"},{"key":"10.1016\/j.blre.2025.101323_bb0140","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1749-6632.2000.tb06651.x","article-title":"Inflamm-aging. An evolutionary perspective on immunosenescence","volume":"908","author":"Franceschi","year":"2000","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.blre.2025.101323_bb0145","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1182\/blood.2020010163","article-title":"CHIP and hips: clonal hematopoiesis is common in patients undergoing hip arthroplasty and is associated with autoimmune disease","volume":"138","author":"Hecker","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101323_bb0150","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.exphem.2017.11.002","article-title":"An inflammatory environment containing TNF\u03b1 favors Tet2-mutant clonal hematopoiesis","volume":"59","author":"Abegunde","year":"2018","journal-title":"Exp Hematol"},{"key":"10.1016\/j.blre.2025.101323_bb0155","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1016\/j.stem.2021.03.002","article-title":"Chronic infection drives Dnmt3a-loss-of-function clonal hematopoiesis via IFN\u03b3 signaling","volume":"28","author":"Hormaechea-Agulla","year":"2021","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.blre.2025.101323_bb0160","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-018-0107-2","article-title":"Clonal hematopoiesis in patients with rheumatoid arthritis","volume":"8","author":"Savola","year":"2018","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.blre.2025.101323_bb0165","doi-asserted-by":"crossref","first-page":"4355","DOI":"10.1093\/rheumatology\/keac108","article-title":"Clonal haematopoiesis of indeterminate potential and cardiovascular events in systemic lupus erythematosus (HEMATOPLUS study)","volume":"61","author":"David","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.blre.2025.101323_bb0170","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1182\/blood.2022015384","article-title":"TET2-mutant clonal hematopoiesis and risk of gout","volume":"140","author":"Agrawal","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101323_bb0175","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13075-023-03014-w","article-title":"Interplay between chronic inflammation and clonal haematopoiesis of indeterminate potential in Beh\u00e7et\u2019s disease","volume":"25","author":"Park","year":"2023","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.blre.2025.101323_bb0180","doi-asserted-by":"crossref","DOI":"10.1093\/ibd\/izae312","article-title":"Clonal hematopoiesis of indeterminate potential in Crohn\u2019s disease and ulcerative colitis","author":"Esai Selvan","year":"2025","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.blre.2025.101323_bb0185","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1038\/s41591-024-03213-1","article-title":"Unidirectional association of clonal hematopoiesis with atherosclerosis development","volume":"30","author":"D\u00edez-D\u00edez","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.blre.2025.101323_bb0190","doi-asserted-by":"crossref","first-page":"7471","DOI":"10.1182\/bloodadvances.2023011578","article-title":"Effects of IL-1\u03b2 inhibition on anemia and clonal hematopoiesis in the randomized CANTOS trial","volume":"7","author":"Woo","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2025.101323_bb0195","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1161\/CIRCULATIONAHA.119.044362","article-title":"Genetic interleukin 6 signaling deficiency attenuates cardiovascular risk in clonal hematopoiesis","volume":"141","author":"Bick","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.blre.2025.101323_bb0200","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1681\/ASN.2022030262","article-title":"Clonal hematopoiesis and CKD progression","volume":"33","author":"Niroula","year":"2022","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.blre.2025.101323_bb0205","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/s41586-023-05857-4","article-title":"Clonal haematopoiesis and risk of chronic liver disease","volume":"616","author":"Wong","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.blre.2025.101323_bb0210","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1182\/blood.2024024187","article-title":"JAK2-mutant clonal hematopoiesis is associated with venous thromboembolism","volume":"144","author":"Zon","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101323_bb0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtha.2025.03.042","article-title":"Clonal hematopoiesis of indeterminate potential (CHIP) and incidence of venous thromboembolism in older adults","author":"Saadatagah","year":"2025","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2025.101323_bb0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.215691","article-title":"Early detection and intervention of clonal hematopoiesis for preventing hematological malignancies","volume":"538","author":"Ye","year":"2022","journal-title":"Cancer Lett"},{"key":"10.1016\/j.blre.2025.101323_bb0225","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1055\/s-2006-945530","article-title":"Major complications following hematopoietic stem cell transplantation","volume":"27","author":"Afessa","year":"2006","journal-title":"Semin Respir Crit Care Med"},{"key":"10.1016\/j.blre.2025.101323_bb0230","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1038\/s41409-021-01214-z","article-title":"Genetics of donor cell leukemia in acute myelogenous leukemia and myelodysplastic syndrome","volume":"56","author":"Williams","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.blre.2025.101323_bb0235","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1182\/blood-2009-03-211797","article-title":"Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996)","volume":"114","author":"Greenberg","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101323_bb0240","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1038\/s41591-024-03188-z","article-title":"Clonal hematopoiesis, cardiovascular events and treatment benefit in 63,700 individuals from five TIMI randomized trials","volume":"30","author":"Marston","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.blre.2025.101323_bb0245","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan8292","article-title":"Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms","volume":"10","author":"Wolach","year":"2018","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.blre.2025.101323_bb0250","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.135204","article-title":"Tet2-mediated clonal hematopoiesis in nonconditioned mice accelerates age-associated cardiac dysfunction","volume":"5","author":"Wang","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.blre.2025.101323_bb0255","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1111\/ejh.13574","article-title":"Clonal cytopenia of undetermined significance (CCUS) with dysplasia is enriched for MDS-type molecular findings compared to CCUS without dysplasia","volume":"106","author":"Jajosky","year":"2021","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.blre.2025.101323_bb0260","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1182\/bloodadvances.2019000770","article-title":"High-sensitivity C-reactive protein is associated with clonal hematopoiesis of indeterminate potential","volume":"4","author":"Busque","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2025.101323_bb0265","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1038\/ng.3610","article-title":"DNMT3A and TET2 compete and cooperate to repress lineage-specific transcription factors in hematopoietic stem cells","volume":"48","author":"Zhang","year":"2016","journal-title":"Nat Genet"},{"key":"10.1016\/j.blre.2025.101323_bb0270","first-page":"1","article-title":"Hematopoietic JAK2(V617F)-mediated clonal hematopoiesis: AIM2 understand mechanisms of atherogenesis","author":"Sano","year":"2021","journal-title":"J Cardiovasc Aging"},{"key":"10.1016\/j.blre.2025.101323_bb0275","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.ccr.2010.11.015","article-title":"Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation","volume":"18","author":"Figueroa","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.blre.2025.101323_bb0280","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/j.cell.2021.01.049","article-title":"Increased stem cell proliferation in atherosclerosis accelerates clonal hematopoiesis","volume":"184","author":"Heyde","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.blre.2025.101323_bb0285","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1161\/CIRCRESAHA.120.317104","article-title":"Clonal hematopoiesis\u2013driver DNMT3A mutations alter immune cells in heart failure","volume":"128","author":"Abplanalp","year":"2021","journal-title":"Circ Res"},{"key":"10.1016\/j.blre.2025.101323_bb0290","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1161\/CIRCULATIONAHA.123.065597","article-title":"Clonal hematopoiesis of indeterminate potential with loss of Tet2 enhances risk for atrial fibrillation through Nlrp3 inflammasome activation","volume":"149","author":"Lin","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.blre.2025.101323_bb0295","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1182\/blood.2022016835","article-title":"Aging drives Tet2+\/\u2212 clonal hematopoiesis via IL-1 signaling","volume":"141","author":"Caiado","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101323_bb0300","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/jdi.12579","article-title":"Adiponectin and pro-inflammatory cytokines are modulated in Vietnamese patients with type 2 diabetes mellitus","volume":"8","author":"Tong","year":"2017","journal-title":"J Diabetes Investig"},{"key":"10.1016\/j.blre.2025.101323_bb0305","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.stem.2018.10.013","article-title":"Inhibition of inflammatory signaling in Tet2 mutant preleukemic cells mitigates stress-induced abnormalities and clonal hematopoiesis","volume":"23","author":"Cai","year":"2018","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.blre.2025.101323_bb0310","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1182\/blood-2016-07-730556","article-title":"The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotype","volume":"128","author":"Basiorka","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101323_bb0315","series-title":"NLRP3-induced systemic inflammation controls the development of JAK2V617F mutant myeloproliferative neoplasms","author":"Koerber","year":"2024"},{"key":"10.1016\/j.blre.2025.101323_bb0320","first-page":"7031","article-title":"Aberrant NLRP3 inflammasome associated with aryl hydrocarbon receptor potentially contributes to the imbalance of T-helper cells in patients with acute myeloid leukemia","volume":"14","author":"Jia","year":"2017","journal-title":"Oncol Lett"},{"key":"10.1016\/j.blre.2025.101323_bb0325","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s00011-016-1012-4","article-title":"Genetic polymorphisms of IL-18 rs1946518 and IL-1\u03b2 rs16944 are associated with prognosis and survival of acute myeloid leukemia","volume":"66","author":"Wang","year":"2017","journal-title":"Inflamm Res"},{"key":"10.1016\/j.blre.2025.101323_bb0330","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s12015-019-09890-7","article-title":"The Nlrp3 inflammasome orchestrates mobilization of bone marrow-residing stem cells into peripheral blood","volume":"15","author":"Lenkiewicz","year":"2019","journal-title":"Stem Cell Rev Rep"},{"key":"10.1016\/j.blre.2025.101323_bb0335","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1146\/annurev-immunol-030409-101311","article-title":"The sterile inflammatory response","volume":"28","author":"Rock","year":"2010","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.blre.2025.101323_bb0340","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0002-9343(02)01484-5","article-title":"Coagulation and activation of inflammatory pathways in the development of functional decline and mortality in the elderly","volume":"114","author":"Cohen","year":"2003","journal-title":"Am J Med"},{"key":"10.1016\/j.blre.2025.101323_bb0345","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/j.1532-5415.1999.tb01583.x","article-title":"Serum IL-6 level and the development of disability in older persons","volume":"47","author":"Ferrucci","year":"1999","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.blre.2025.101323_bb0350","doi-asserted-by":"crossref","first-page":"9194","DOI":"10.1073\/pnas.0503280102","article-title":"Cell intrinsic alterations underlie hematopoietic stem cell aging","volume":"102","author":"Rossi","year":"2005","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.blre.2025.101323_bb0355","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1084\/jem.20111490","article-title":"Clonal analysis reveals multiple functional defects of aged murine hematopoietic stem cells","volume":"208","author":"Dykstra","year":"2011","journal-title":"J Exp Med"},{"key":"10.1016\/j.blre.2025.101323_bb0360","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1182\/blood-2004-07-2599","article-title":"The origins of age-related proinflammatory state","volume":"105","author":"Ferrucci","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101323_bb0365","doi-asserted-by":"crossref","first-page":"20012","DOI":"10.1073\/pnas.1116110108","article-title":"Human bone marrow hematopoietic stem cells are increased in frequency and myeloid-biased with age","volume":"108","author":"Pang","year":"2011","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.blre.2025.101323_bb0370","article-title":"NLRP3 inflammasome promotes the progression of acute myeloid leukemia via IL-1\u03b2 pathway","volume":"12","author":"Zhong","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.blre.2025.101323_bb0375","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.humimm.2020.09.001","article-title":"Genetic polymorphisms and expression of NLRP3 inflammasome-related genes are associated with Philadelphia chromosome-negative myeloproliferative neoplasms","volume":"81","author":"Zhou","year":"2020","journal-title":"Hum Immunol"},{"key":"10.1016\/j.blre.2025.101323_bb0380","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1182\/bloodadvances.2023011338","article-title":"IL-1\u03b2 promotes MPN disease initiation by favoring early clonal expansion of JAK2-mutant hematopoietic stem cells","volume":"8","author":"Rai","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2025.101323_bb0385","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1001\/jamacardio.2020.2468","article-title":"Association of clonal hematopoiesis of indeterminate potential with inflammatory gene expression in patients with severe degenerative aortic valve stenosis or chronic postischemic heart failure","volume":"5","author":"Abplanalp","year":"2020","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.blre.2025.101323_bb0390","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.jacc.2017.12.037","article-title":"Tet2-mediated clonal hematopoiesis accelerates heart failure through a mechanism involving the IL-1\u03b2\/NLRP3 inflammasome","volume":"71","author":"Sano","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.blre.2025.101323_bb0395","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1111\/bjh.19530","article-title":"Inflammatory profile of lower risk myelodysplastic syndromes","volume":"205","author":"Topping","year":"2024","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2025.101323_bb0400","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000713","article-title":"Inflammatory cytokine profiles do not differ between patients with idiopathic cytopenias of undetermined significance and myelodysplastic syndromes","volume":"6","author":"Nielsen","year":"2022","journal-title":"HemaSphere"},{"key":"10.1016\/j.blre.2025.101323_bb0405","doi-asserted-by":"crossref","first-page":"787","DOI":"10.4049\/jimmunol.0901363","article-title":"Cutting edge: NF-kappaB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression","volume":"183","author":"Bauernfeind","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.blre.2025.101323_bb0410","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.bbrc.2012.07.011","article-title":"Oxidized low-density lipoprotein induces secretion of interleukin-1\u03b2 by macrophages via reactive oxygen species-dependent NLRP3 inflammasome activation","volume":"425","author":"Jiang","year":"2012","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.blre.2025.101323_bb0415","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1002\/eji.201948427","article-title":"Sestrin1 inhibits oxidized low-density lipoprotein-induced activation of NLRP3 inflammasome in macrophages in a murine atherosclerosis model","volume":"50","author":"Keping","year":"2020","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.blre.2025.101323_bb0420","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s10571-016-0356-1","article-title":"Neuroprotective effects of resatorvid against traumatic brain injury in rat: involvement of neuronal autophagy and TLR4 signaling pathway","volume":"37","author":"Feng","year":"2017","journal-title":"Cell Mol Neurobiol"},{"key":"10.1016\/j.blre.2025.101323_bb0425","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1080\/14728222.2020.1752182","article-title":"Targeting TLR4-dependent inflammation in post-hemorrhagic brain injury","volume":"24","author":"Karimy","year":"2020","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.blre.2025.101323_bb0430","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1182\/blood-2002-01-0151","article-title":"Bay 11\u20137082 inhibits transcription factor NF-\u03baB and induces apoptosis of HTLV-I\u2013infected T-cell lines and primary adult T-cell leukemia cells","volume":"100","author":"Mori","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101323_bb0435","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/j.1365-2141.2009.07988.x","article-title":"IKK inhibitor bay 11\u20137082 induces necroptotic cell death in precursor-B acute lymphoblastic leukaemic blasts","volume":"148","author":"Meng","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2025.101323_bb0440","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1038\/s41375-022-01573-6","article-title":"Cystine uptake inhibition potentiates front-line therapies in acute myeloid leukemia","volume":"36","author":"Pardieu","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2025.101323_bb0445","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1074\/jbc.M608083200","article-title":"ATP activates a reactive oxygen species-dependent oxidative stress response and secretion of proinflammatory cytokines in macrophages","volume":"282","author":"Cruz","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1016\/j.blre.2025.101323_bb0450","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0072138","article-title":"S100A8 and S100A9 induce cytokine expression and regulate the NLRP3 inflammasome via ROS-dependent activation of NF-\u03baB1","volume":"8","author":"Simard","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.blre.2025.101323_bb0455","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1182\/blood-2020-137482","article-title":"A phase 1 study of tasquinimod in patients with relapsed or refractory multiple myeloma","volume":"136","author":"Vogl","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101323_bb0460","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1158\/1538-7445.AM2025-2127","article-title":"Abstract 2127: Efficacy of monoclonal antibodies against pathogenic S100A8\/9 in myelodysplasia and leukemia models","volume":"85","author":"Sanawar","year":"2025","journal-title":"Cancer Res"},{"key":"10.1016\/j.blre.2025.101323_bb0465","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S1097-2765(02)00599-3","article-title":"The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-&#x3b2","volume":"10","author":"Martinon","year":"2002","journal-title":"Mol Cell"},{"key":"10.1016\/j.blre.2025.101323_bb0470","doi-asserted-by":"crossref","first-page":"8041","DOI":"10.1073\/pnas.0611496104","article-title":"Cryopyrin\/NALP3 binds ATP\/dATP, is an ATPase, and requires ATP binding to mediate inflammatory signaling","volume":"104","author":"Duncan","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.blre.2025.101323_bb0475","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.3000354","article-title":"MCC950\/CRID3 potently targets the NACHT domain of wild-type NLRP3 but not disease-associated mutants for inflammasome inhibition","volume":"17","author":"Vande Walle","year":"2019","journal-title":"PLoS Biol"},{"key":"10.1016\/j.blre.2025.101323_bb0480","doi-asserted-by":"crossref","first-page":"19305","DOI":"10.1038\/s41598-021-98437-3","article-title":"The selective NLRP3 inhibitor MCC950 hinders atherosclerosis development by attenuating inflammation and pyroptosis in macrophages","volume":"11","author":"Zeng","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.blre.2025.101323_bb0485","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1161\/ATVBAHA.117.309575","article-title":"NLRP3 inflammasome inhibition by MCC950 reduces atherosclerotic lesion development in apolipoprotein E-deficient mice-brief report","volume":"37","author":"van der Heijden","year":"2017","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.blre.2025.101323_bb0490","doi-asserted-by":"crossref","DOI":"10.1172\/JCI163968","article-title":"Obesity-induced inflammation exacerbates clonal hematopoiesis","volume":"133","author":"Pasupuleti","year":"2023","journal-title":"J Clin Invest"},{"key":"10.1016\/j.blre.2025.101323_bb0495","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1161\/CIRCRESAHA.124.324492","article-title":"Experimental TET2 clonal hematopoiesis predisposes to renal hypertension through an inflammasome-mediated mechanism","volume":"135","author":"Polizio","year":"2024","journal-title":"Circ Res"},{"key":"10.1016\/j.blre.2025.101323_bb0500","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/nrd.2018.97","article-title":"Targeting the NLRP3 inflammasome in inflammatory diseases","volume":"17","author":"Mangan","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.blre.2025.101323_bb0505","doi-asserted-by":"crossref","DOI":"10.1111\/cts.13789","article-title":"First-in-human safety, tolerability, and pharmacokinetic results of DFV890, an oral low-molecular-weight NLRP3 inhibitor","volume":"17","author":"Gatlik","year":"2024","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.blre.2025.101323_bb0510","series-title":"An open-label, single arm phase II study of DFV890 to assess the safety, tolerability and efficacy in participants with familial cold auto-inflammatory syndrome (FCAS)","author":"Novartis Pharmaceuticals","year":"2021"},{"key":"10.1016\/j.blre.2025.101323_bb0515","series-title":"A randomized, two-arm, placebo-controlled, participant and investigator-blinded study investigating the efficacy, safety and tolerability of DFV890 in patients with symptomatic knee osteoarthritis","author":"Novartis Pharmaceuticals","year":"2021"},{"key":"10.1016\/j.blre.2025.101323_bb0520","series-title":"A phase 1b, open label, multi-center, dose optimization and dose expansion study to assess the safety and efficacy of DFV890 in adult patients with myeloid diseases","author":"Novartis Pharmaceuticals","year":"2022"},{"key":"10.1016\/j.blre.2025.101323_bb0525","doi-asserted-by":"crossref","first-page":"3250","DOI":"10.1182\/blood-2023-174642","article-title":"Safety and preliminary efficacy of DFV890 in adult patients with myeloid diseases: a phase 1b study","volume":"142","author":"Garcia-Manero","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101323_bb0530","author":"Novartis Pharmaceuticals","year":"2023"},{"key":"10.1016\/j.blre.2025.101323_bb0535","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.atherosclerosis.2022.03.005","article-title":"Blocking the NLRP3 inflammasome reduces osteogenic calcification and M1 macrophage polarization in a mouse model of calcified aortic valve stenosis","volume":"347","author":"Lu","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.blre.2025.101323_bb0540","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.107358","article-title":"NLRP3 inflammasome inhibitor INF39 attenuated NLRP3 assembly in macrophages","volume":"92","author":"Shi","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.blre.2025.101323_bb0545","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1038\/s41467-018-04947-6","article-title":"Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity","volume":"9","author":"He","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.blre.2025.101323_bb0550","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexcr.2020.111847","article-title":"VX-765 attenuates atherosclerosis in ApoE deficient mice by modulating VSMCs pyroptosis","volume":"389","author":"Li","year":"2020","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.blre.2025.101323_bb0555","article-title":"Application of disulfiram and its metabolites in treatment of inflammatory disorders","volume":"12","author":"Guo","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.blre.2025.101323_bb0560","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.immuni.2017.11.013","article-title":"The pore-forming protein Gasdermin D regulates Interleukin-1 secretion from living macrophages","volume":"48","author":"Evavold","year":"2018","journal-title":"Immunity"},{"key":"10.1016\/j.blre.2025.101323_bb0565","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1038\/356768a0","article-title":"A novel heterodimeric cysteine protease is required for interleukin-1\u03b2processing in monocytes","volume":"356","author":"Thornberry","year":"1992","journal-title":"Nature"},{"key":"10.1016\/j.blre.2025.101323_bb0570","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1002\/eji.201141550","article-title":"A clinical perspective of IL-1\u03b2 as the gatekeeper of inflammation","volume":"41","author":"Dinarello","year":"2011","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.blre.2025.101323_bb0575","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.1016\/j.celrep.2017.03.018","article-title":"Identification of Interleukin-1 by functional screening as a key mediator of cellular expansion and disease progression in acute myeloid leukemia","volume":"18","author":"Carey","year":"2017","journal-title":"Cell Rep"},{"key":"10.1016\/j.blre.2025.101323_bb0580","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.ccr.2010.11.015","article-title":"Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation","volume":"18","author":"Figueroa","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.blre.2025.101323_bb0585","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ccr.2011.06.001","article-title":"Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation","volume":"20","author":"Moran-Crusio","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.blre.2025.101323_bb0590","doi-asserted-by":"crossref","first-page":"8102","DOI":"10.1038\/s41467-023-43697-y","article-title":"Clonal hematopoiesis related TET2 loss-of-function impedes IL1\u03b2-mediated epigenetic reprogramming in hematopoietic stem and progenitor cells","volume":"14","author":"McClatchy","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.blre.2025.101323_bb0595","doi-asserted-by":"crossref","first-page":"S99","DOI":"10.1016\/j.exphem.2023.06.206","article-title":"Effect of IL-1b-induced inflammation on TET2-mutant clonal hematopoeisis in human models","volume":"124","author":"Kasbekar","year":"2023","journal-title":"Exp Hematol"},{"key":"10.1016\/j.blre.2025.101323_bb0600","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/s44161-023-00405-9","article-title":"Suppression of IL-1\u03b2 promotes beneficial accumulation of fibroblast-like cells in atherosclerotic plaques in clonal hematopoiesis","volume":"3","author":"Fidler","year":"2024","journal-title":"Nat Cardiovasc Res"},{"key":"10.1016\/j.blre.2025.101323_bb0605","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa0810787","article-title":"Use of canakinumab in the cryopyrin-associated periodic syndrome","volume":"360","author":"Lachmann","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2025.101323_bb0610","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1056\/NEJMoa1205099","article-title":"Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis","volume":"367","author":"Ruperto","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2025.101323_bb0615","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2025.101323_bb0620","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1200\/JCO.23.00910","article-title":"Canakinumab as adjuvant therapy in patients with completely resected non-small-cell lung cancer: results from the CANOPY-a double-blind, randomized clinical trial","volume":"42","author":"Garon","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2025.101323_bb0625","unstructured":"A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP. 2011."},{"key":"10.1016\/j.blre.2025.101323_bb0630","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1001\/jamacardio.2022.0386","article-title":"TET2-driven clonal hematopoiesis and response to canakinumab: an exploratory analysis of the CANTOS randomized clinical trial","volume":"7","author":"Svensson","year":"2022","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.blre.2025.101323_bb0635","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1161\/CIRCULATIONAHA.118.038010","article-title":"Anti-inflammatory therapy with canakinumab for the prevention of hospitalization for heart failure","volume":"139","author":"Everett","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.blre.2025.101323_bb0640","article-title":"Abstract 15111: TET2-driven clonal hematopoiesis predicts enhanced response to canakinumab in the CANTOS trial: an exploratory analysis","volume":"138","author":"Svensson","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.blre.2025.101323_bb0645","series-title":"Effects of IL-1 beta inhibition on vascular inflammation in TET2 clonal hematopoiesis","year":"2024"},{"key":"10.1016\/j.blre.2025.101323_bb0650","series-title":"A randomized double-blind placebo-controlled phase II multi-center study of inflammation modification of canakinumab to prevent leukemic progression of clonal cytopenias of unknown significance (CCUS): IMPACT study","year":"2022"},{"key":"10.1016\/j.blre.2025.101323_bb0655","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1056\/NEJMe1709904","article-title":"Targeting inflammation in coronary artery disease","volume":"377","author":"Harrington","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2025.101323_bb0660","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.cjco.2022.01.003","article-title":"Cost-effectiveness of canakinumab from a Canadian perspective for recurrent cardiovascular events","volume":"4","author":"Boczar","year":"2022","journal-title":"CJC Open"},{"key":"10.1016\/j.blre.2025.101323_bb0665","first-page":"39","article-title":"358. Understanding and mitigating the risk of infection with canakinumab","author":"Libby","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.blre.2025.101323_bb0670","doi-asserted-by":"crossref","first-page":"10786","DOI":"10.1073\/pnas.1422749112","article-title":"Antibodies targeting human IL1RAP (IL1R3) show therapeutic effects in xenograft models of acute myeloid leukemia","volume":"112","author":"\u00c5gerstam","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.blre.2025.101323_bb0675","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1200\/JCO.2010.32.9490","article-title":"Circulating Interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study","volume":"29","author":"Tefferi","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2025.101323_bb0680","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.stem.2013.06.009","article-title":"Myeloproliferative neoplasia remodels the endosteal bone marrow niche into a self-reinforcing leukemic niche","volume":"13","author":"Schepers","year":"2013","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.blre.2025.101323_bb0685","doi-asserted-by":"crossref","first-page":"11477","DOI":"10.1074\/jbc.270.19.11477","article-title":"Mapping receptor binding sites in Interleukin (IL)-1 receptor antagonist and IL-1\u03b2 by site-directed mutagenesis: identification of a single site in IL-1ra and two sites in IL-1\u03b2","volume":"270","author":"Evans","year":"1995","journal-title":"J Biol Chem"},{"key":"10.1016\/j.blre.2025.101323_bb0690","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1016\/j.amjcard.2013.01.287","article-title":"Effects of interleukin-1 blockade with anakinra on adverse cardiac remodeling and heart failure after acute myocardial infarction [from the Virginia Commonwealth University-Anakinra Remodeling Trial (2) (VCU-ART2) pilot study]","volume":"111","author":"Abbate","year":"2013","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.blre.2025.101323_bb0695","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.amjcard.2014.11.003","article-title":"Comparative safety of interleukin-1 blockade with anakinra in patients with ST-segment elevation acute myocardial infarction (from the VCU-ART and VCU-ART2 pilot studies)","volume":"115","author":"Abbate","year":"2015","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.blre.2025.101323_bb0700","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1056\/NEJMoa2027892","article-title":"Phase 3 trial of Interleukin-1 trap rilonacept in recurrent pericarditis","volume":"384","author":"Klein","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2025.101323_bb0705","doi-asserted-by":"crossref","first-page":"2707","DOI":"10.4049\/jimmunol.1101737","article-title":"Cutting edge: IL-6 is a marker of inflammation with no direct role in inflammasome-mediated mouse models","volume":"189","author":"McGeough","year":"2012","journal-title":"J Immunol"},{"key":"10.1016\/j.blre.2025.101323_bb0710","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.ccr.2011.10.012","article-title":"IL-6 controls leukemic multipotent progenitor cell fate and contributes to chronic myelogenous leukemia development","volume":"20","author":"Reynaud","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.blre.2025.101323_bb0715","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1161\/01.CIR.101.15.1767","article-title":"Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men","volume":"101","author":"Ridker","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.blre.2025.101323_bb0720","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/nature15252","article-title":"Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6","volume":"525","author":"Zhang","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.blre.2025.101323_bb0725","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1161\/CIRCULATIONAHA.122.062126","article-title":"Interleukin-6 receptor polymorphism attenuates clonal hematopoiesis-mediated coronary artery disease risk among 451 180 individuals in the UK Biobank","volume":"147","author":"Vlasschaert","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.blre.2025.101323_bb0730","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2017-000496","article-title":"Impact of tocilizumab monotherapy on patient-reported outcomes in patients with rheumatoid arthritis from two randomised controlled trials","volume":"3","author":"Strand","year":"2017","journal-title":"RMD Open"},{"key":"10.1016\/j.blre.2025.101323_bb0735","unstructured":"A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate Reduction in Inflammation in Patients With Advanced Chronic Renal Disease Utilizing Antibody-Mediated Interleukin-6 Inhibition in Japan. In: Sponsor: Corvidia Therapeutics Inc asoNNAS, editor.2020."},{"key":"10.1016\/j.blre.2025.101323_bb0740","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1016\/S0140-6736(21)00520-1","article-title":"IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"397","author":"Ridker","year":"2021","journal-title":"The Lancet"},{"key":"10.1016\/j.blre.2025.101323_bb0745","doi-asserted-by":"crossref","DOI":"10.1172\/JCI152673","article-title":"Bone marrow-confined IL-6 signaling mediates the progression of myelodysplastic syndromes to acute myeloid leukemia","volume":"132","author":"Mei","year":"2022","journal-title":"J Clin Invest"},{"key":"10.1016\/j.blre.2025.101323_bb0750","series-title":"A phase 2b \/ 3, multicenter, randomized, double-blind, placebo-controlled, combined dose-finding and cardiovascular outcome study to investigate the efficacy and safety of CSL300 (Clazakizumab) in subjects with end stage kidney disease undergoing dialysis","year":"2022"},{"key":"10.1016\/j.blre.2025.101323_bb0755","series-title":"A phase 2, randomized, double-blind, placebo-controlled study to evaluate quarterly and monthly TOUR006 in participants with chronic kidney disease and elevated high-sensitivity C-reactive protein","year":"2024"},{"key":"10.1016\/j.blre.2025.101323_bb0760","first-page":"495","article-title":"Infection risk with the use of interleukin inhibitors in hospitalized patients with COVID-19: a narrative review","volume":"29","author":"Koritala","year":"2021","journal-title":"Infez Med"},{"key":"10.1016\/j.blre.2025.101323_bb0765","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.leukres.2015.06.015","article-title":"DNMT3A intragenic hypomethylation is associated with adverse prognosis in acute myeloid leukemia","volume":"39","author":"Zhang","year":"2015","journal-title":"Leuk Res"},{"key":"10.1016\/j.blre.2025.101323_bb0770","doi-asserted-by":"crossref","first-page":"679","DOI":"10.3324\/haematol.2017.182444","article-title":"Histone modifier gene mutations in peripheral T-cell lymphoma not otherwise specified","volume":"103","author":"Ji","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2025.101323_bb0775","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/890","article-title":"Cloning and characterization of a family of novel mammalian DNA (cytosine-5) methyltransferases","volume":"19","author":"Okano","year":"1998","journal-title":"Nat Genet"},{"key":"10.1016\/j.blre.2025.101323_bb0780","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/ng.1009","article-title":"Dnmt3a is essential for hematopoietic stem cell differentiation","volume":"44","author":"Challen","year":"2011","journal-title":"Nat Genet"},{"key":"10.1016\/j.blre.2025.101323_bb0785","doi-asserted-by":"crossref","first-page":"14566","DOI":"10.1073\/pnas.1112317108","article-title":"Ten-Eleven-Translocation 2 (TET2) negatively regulates homeostasis and differentiation of hematopoietic stem cells in mice","volume":"108","author":"Ko","year":"2011","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.blre.2025.101323_bb0790","doi-asserted-by":"crossref","first-page":"6061","DOI":"10.1038\/s41467-021-26093-2","article-title":"TET2 mutations are associated with hypermethylation at key regulatory enhancers in normal and malignant hematopoiesis","volume":"12","author":"Tulstrup","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.blre.2025.101323_bb0795","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.exphem.2022.09.003","article-title":"Role of ASXL1 in hematopoiesis and myeloid diseases","volume":"115","author":"Gao","year":"2022","journal-title":"Exp Hematol"},{"key":"10.1016\/j.blre.2025.101323_bb0800","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2025.101323_bb0805","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1177\/2040620716674677","article-title":"Safety and efficacy of azacitidine in elderly patients with intermediate to high-risk myelodysplastic syndromes","volume":"8","author":"Navada","year":"2017","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.blre.2025.101323_bb0810","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1002\/cncr.22508","article-title":"Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome","volume":"109","author":"Kantarjian","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.blre.2025.101323_bb0815","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1200\/JCO.2002.04.117","article-title":"Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B","volume":"20","author":"Silverman","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2025.101323_bb0820","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/ijc.23607","article-title":"Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine","volume":"123","author":"Stresemann","year":"2008","journal-title":"Int J Cancer"},{"key":"10.1016\/j.blre.2025.101323_bb0825","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1038\/leu.2011.71","article-title":"Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias","volume":"25","author":"Itzykson","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2025.101323_bb0830","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1182\/blood-2014-06-582809","article-title":"TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients","volume":"124","author":"Bejar","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101323_bb0835","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/s41408-021-00439-x","article-title":"Treatment outcome of clonal cytopenias of undetermined significance: a single-institution retrospective study","volume":"11","author":"Xie","year":"2021","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.blre.2025.101323_bb0840","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/S2352-3026(23)00338-1","article-title":"Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study","volume":"11","author":"Garcia-Manero","year":"2024","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.blre.2025.101323_bb0845","unstructured":"A Multi-Site Break Through Cancer Pilot Study Testing the Feasibility and Safety of Therapeutic Intervention for Patients with High-risk Clonal Cytopenia of Undetermined Significance (CCUS). In: Astex Pharmaceuticals I, Break Through C, editors.2025."},{"key":"10.1016\/j.blre.2025.101323_bb0850","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1182\/blood-2017-06-788497","article-title":"Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS\/MPN","volume":"130","author":"Jabbour","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101323_bb0855","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200034","article-title":"Low-dose decitabine versus low-dose azacitidine in lower-risk MDS","volume":"1","author":"Sasaki","year":"2022","journal-title":"NEJM Evid"},{"key":"10.1016\/j.blre.2025.101323_bb0860","first-page":"1878","article-title":"Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer1","volume":"60","author":"Browder","year":"2000","journal-title":"Cancer Res"},{"key":"10.1016\/j.blre.2025.101323_bb0865","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1182\/blood.2024025834","article-title":"A weekly low-dose regimen of decitabine and venetoclax is efficacious and less myelotoxic in a racially diverse cohort","volume":"144","author":"Goldfinger","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101323_bb0870","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/nature23876","article-title":"Ascorbate regulates haematopoietic stem cell function and leukaemogenesis","volume":"549","author":"Agathocleous","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.blre.2025.101323_bb0875","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2110758118","article-title":"TET2 as a tumor suppressor and therapeutic target in T-cell acute lymphoblastic leukemia","volume":"118","author":"Bensberg","year":"2021","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.blre.2025.101323_bb0880","series-title":"Epigenetics, vitamin C, and abnormal hematopoiesis - Role of vitamin C in epigenetic regulation in hematopoiesis sub-study on CCUS, low-risk MDS, and CMML-0\/1 [NCT03682029]","year":"2025"},{"key":"10.1016\/j.blre.2025.101323_bb0885","series-title":"Phase 2 trial of high dose intravenous ascorbic acid as an adjunct to salvage chemotherapy in relapsed\/ refractory lymphoma, patients with clonal cytopenia of undetermined significance, and chronic myelomonocytic leukemia [NCT03418038]","year":"2025"},{"key":"10.1016\/j.blre.2025.101323_bb0890","doi-asserted-by":"crossref","first-page":"8749","DOI":"10.1073\/pnas.0702854104","article-title":"Ascorbate in pharmacologic concentrations selectively generates ascorbate radical and hydrogen peroxide in extracellular fluid in vivo","volume":"104","author":"Chen","year":"2007","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.blre.2025.101323_bb0895","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.redox.2016.10.010","article-title":"Tumor cells have decreased ability to metabolize H2O2: implications for pharmacological ascorbate in cancer therapy","volume":"10","author":"Doskey","year":"2016","journal-title":"Redox Biol"},{"key":"10.1016\/j.blre.2025.101323_bb0900","doi-asserted-by":"crossref","first-page":"533","DOI":"10.7326\/0003-4819-140-7-200404060-00010","article-title":"Vitamin C pharmacokinetics: implications for oral and intravenous use","volume":"140","author":"Padayatty","year":"2004","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.blre.2025.101323_bb0905","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1182\/blood.2024024962","article-title":"High-dose IV ascorbic acid therapy for patients with CCUS with TET2 mutations","volume":"144","author":"Xie","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101323_bb0910","doi-asserted-by":"crossref","first-page":"6699","DOI":"10.1182\/blood-2024-203486","article-title":"Phase II trial assessing safety and preliminary efficacy of high-dose intravenous ascorbic acid and decitabine in TET2-mutant chronic myelomonocytic leukemia","volume":"144","author":"McCullough","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101323_bb0915","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa1002028","article-title":"Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis","volume":"363","author":"Verstovsek","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2025.101323_bb0920","doi-asserted-by":"crossref","first-page":"3542","DOI":"10.1182\/blood-2014-12-618090","article-title":"TGF-\u03b2 signaling in the control of hematopoietic stem cells","volume":"125","author":"Blank","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101323_bb0925","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2022.100068","article-title":"A lower frequency of spliceosome mutations distinguishes clonal cytopenias of undetermined significance from low-risk myelodysplastic syndromes, despite inherent similarities in genomic, laboratory, and clinical features","volume":"36","author":"Ferrone","year":"2023","journal-title":"Mod Pathol"},{"key":"10.1016\/j.blre.2025.101323_bb0930","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijcard.2024.132184","article-title":"The clonal hematopoiesis mutation Jak2V617F aggravates endothelial injury and thrombosis in arteries with erosion-like intimas","volume":"409","author":"Molinaro","year":"2024","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.blre.2025.101323_bb0935","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1056\/NEJMoa1409405","article-title":"Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence","volume":"371","author":"Genovese","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2025.101323_bb0940","doi-asserted-by":"crossref","first-page":"5128","DOI":"10.1182\/blood-2012-07-444067","article-title":"Development and validation of an International Prognostic Score of thrombosis in World Health Organization\u2013essential thrombocythemia (IPSET-thrombosis)","volume":"120","author":"Barbui","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101323_bb0945","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1161\/CIRCRESAHA.118.313283","article-title":"Macrophage inflammation, erythrophagocytosis, and accelerated atherosclerosis in Jak2 (V617F) mice","volume":"123","author":"Wang","year":"2018","journal-title":"Circ Res"},{"key":"10.1016\/j.blre.2025.101323_bb0950","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1002\/art.33419","article-title":"A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone","volume":"64","author":"Kremer","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.blre.2025.101323_bb0955","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1136\/annrheumdis-2019-eular.2994","article-title":"THU0181 treatment with upadacitinib results in the normalization of key pathobiologic pathways in patients with rheumatoid arthritis: biomarker results from the phase 3 select-next and select-beyond studies","volume":"78","author":"Sornasse","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.blre.2025.101323_bb0960","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1056\/NEJMoa1409002","article-title":"Ruxolitinib versus standard therapy for the treatment of polycythemia vera","volume":"372","author":"Vannucchi","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2025.101323_bb0965","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2025.101323_bb0970","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1158\/2159-8290.CD-23-1092","article-title":"CRISPR dependency screens in primary hematopoietic stem cells identify KDM3B as a genotype-specific vulnerability in IDH2- and TET2-mutant cells","volume":"14","author":"Waarts","year":"2024","journal-title":"Cancer Discov"},{"key":"10.1016\/j.blre.2025.101323_bb0975","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41375-020-0954-2","article-title":"Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis","volume":"35","author":"Talpaz","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2025.101323_bb0980","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s10557-020-06943-9","article-title":"Inhibition of JAK2 suppresses myelopoiesis and atherosclerosis in Apoe\u2212\/\u2212 mice","volume":"34","author":"Tang","year":"2020","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.blre.2025.101323_bb0985","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ccell.2017.11.009","article-title":"Dual targeting of oncogenic activation and inflammatory signaling increases therapeutic efficacy in myeloproliferative neoplasms","volume":"33","author":"Kleppe","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.blre.2025.101323_bb0990","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1001\/jamaoncol.2017.5818","article-title":"Pacritinib vs best available therapy, including ruxolitinib, in patients with myelofibrosis: a randomized clinical trial","volume":"4","author":"Mascarenhas","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.blre.2025.101323_bb0995","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2147\/JEP.S110702","article-title":"Comprehensive kinase profile of pacritinib, a nonmyelosuppressive Janus kinase 2 inhibitor","volume":"8","author":"Singer","year":"2016","journal-title":"J Exp Pharmacol"},{"key":"10.1016\/j.blre.2025.101323_bb1000","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ccr.2013.05.006","article-title":"Targeting IRAK1 as a therapeutic approach for myelodysplastic syndrome","volume":"24","author":"Rhyasen Garrett","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1016\/j.blre.2025.101323_bb1005","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1002\/jha2.591","article-title":"Risk-adjusted safety analysis of the oral JAK2\/IRAK1 inhibitor pacritinib in patients with myelofibrosis","volume":"3","author":"Pemmaraju","year":"2022","journal-title":"eJHaem"},{"key":"10.1016\/j.blre.2025.101323_bb1010","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/s41408-021-00526-z","article-title":"Efficacy and tolerability of Janus kinase inhibitors in myelofibrosis: a systematic review and network meta-analysis","volume":"11","author":"Sureau","year":"2021","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.blre.2025.101323_bb1015","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/S1470-2045(21)00494-0","article-title":"Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial","volume":"22","author":"DiNardo","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.blre.2025.101323_bb1020","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","article-title":"Durable remissions with ivosidenib in <i>IDH1<\/i>\u2212mutated relapsed or refractory AML","volume":"378","author":"DiNardo","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2025.101323_bb1025","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1158\/2643-3230.BCD-23-0195","article-title":"IDH1-mutant preleukemic hematopoietic stem cells can be eliminated by inhibition of oxidative phosphorylation","volume":"5","author":"Landberg","year":"2024","journal-title":"Blood Cancer Discov"},{"key":"10.1016\/j.blre.2025.101323_bb1030","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ccr.2010.01.020","article-title":"The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate","volume":"17","author":"Ward","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.blre.2025.101323_bb1035","series-title":"A pilot study of ivosidenib for patients with clonal cytopenia of undetermined significance and mutations in IDH1","year":"2021"},{"key":"10.1016\/j.blre.2025.101323_bb1040","series-title":"A pilot study of enasidenib for patients with clonal cytopenia of undetermined significance and mutations in IDH2: a decentralized trial","year":"2024"},{"key":"10.1016\/j.blre.2025.101323_bb1045","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S0140-6736(23)00874-7","article-title":"Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial","volume":"402","author":"Platzbecker","year":"2023","journal-title":"The Lancet"},{"key":"10.1016\/j.blre.2025.101323_bb1050","series-title":"FDA approves luspatercept as first-line anemia treatment in patients with lower-risk MDS","author":"Munz","year":"2023"},{"key":"10.1016\/j.blre.2025.101323_bb1055","doi-asserted-by":"crossref","first-page":"3434","DOI":"10.1182\/blood-2008-02-139824","article-title":"Inhibition of the TGF-\u03b2 receptor I kinase promotes hematopoiesis in MDS","volume":"112","author":"Zhou","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101323_bb1060","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1038\/s41375-019-0420-1","article-title":"The role of TGF\u03b2 in hematopoiesis and myeloid disorders","volume":"33","author":"Bataller","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2025.101323_bb1065","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1038\/nm.3512","article-title":"Transforming growth factor-\u03b2 superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis","volume":"20","author":"Suragani","year":"2014","journal-title":"Nat Med"},{"key":"10.1016\/j.blre.2025.101323_bb1070","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1182\/blood-2023-178666","article-title":"Clonal hematopoiesis-related mutations are associated with favorable clinical benefit following luspatercept treatment in patients with lower-risk myelodysplastic syndromes: a subgroup analysis from the phase 3 COMMANDS trial","volume":"142","author":"Hasan","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101323_bb1075","doi-asserted-by":"crossref","first-page":"4046","DOI":"10.1182\/blood-2024-194241","article-title":"Luspatercept reduces clonal hematopoiesis-associated cardiac stress via modulation of mTORC1 and inflammatory signaling pathways","volume":"144","author":"Hasan","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101323_bb1080","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.ccell.2015.04.006","article-title":"SRSF2 mutations contribute to myelodysplasia by mutant-specific effects on exon recognition","volume":"27","author":"Kim","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.blre.2025.101323_bb1085","series-title":"An open-label, multicenter phase 1 trial to evaluate the safety, pharmacokinetics and pharmacodynamics of splicing modulator H3B-8800 for subjects with myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia","year":"2016"},{"key":"10.1016\/j.blre.2025.101323_bb1090","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0011765","article-title":"Cholesterol crystals activate the NLRP3 inflammasome in human macrophages: a novel link between cholesterol metabolism and inflammation","volume":"5","author":"Rajam\u00e4ki","year":"2010","journal-title":"PloS One"},{"key":"10.1016\/j.blre.2025.101323_bb1095","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/MCA.0000000000000255","article-title":"NLRP3 inflammasome in peripheral blood monocytes of acute coronary syndrome patients and its relationship with statins","volume":"26","author":"Altaf","year":"2015","journal-title":"Coron Artery Dis"},{"key":"10.1016\/j.blre.2025.101323_bb1100","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1182\/blood-2024-203136","article-title":"Statin therapy is associated with reduced clonal expansion in TET2 mutated clonal haematopoiesis of indeterminate potential","volume":"144","author":"Nuttall Musson","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101323_bb1105","doi-asserted-by":"crossref","first-page":"3838","DOI":"10.1182\/bloodadvances.2023009818","article-title":"Statin use in myelodysplastic syndromes is associated with a better survival and decreased progression to leukemia","volume":"7","author":"Afzal","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2025.101323_bb1110","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.51927","article-title":"Clonal hematopoiesis risk score and all-cause and cardiovascular mortality in older adults","volume":"7","author":"Saadatagah","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.blre.2025.101323_bb1115","series-title":"Pilot study of statins in patients with clonal cytopenia of undetermined significance (CCUS) and myelodysplastic syndromes (MDS)","year":"2022"},{"key":"10.1016\/j.blre.2025.101323_bb1120","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.7150\/ijbs.29680","article-title":"Metformin inhibits the NLRP3 inflammasome via AMPK\/mTOR-dependent effects in diabetic cardiomyopathy","volume":"15","author":"Yang","year":"2019","journal-title":"Int J Biol Sci"},{"key":"10.1016\/j.blre.2025.101323_bb1125","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1038\/s41375-018-0368-6","article-title":"Sequentially inducible mouse models reveal that Npm1 mutation causes malignant transformation of Dnmt3a-mutant clonal hematopoiesis","volume":"33","author":"Loberg","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2025.101323_bb1130","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.1038\/s41467-025-57238-2","article-title":"Elevated mitochondrial membrane potential is a therapeutic vulnerability in Dnmt3a-mutant clonal hematopoiesis","volume":"16","author":"Young","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.blre.2025.101323_bb1135","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41586-025-08871-w","article-title":"Metformin reduces the competitive advantage of Dnmt3aR878H HSPCs","volume":"642","author":"Hosseini","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.blre.2025.101323_bb1140","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1126\/science.ade3332","article-title":"Structural basis of mammalian respiratory complex I inhibition by medicinal biguanides","volume":"379","author":"Bridges","year":"2023","journal-title":"Science"},{"key":"10.1016\/j.blre.2025.101323_bb1145","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1158\/2159-8290.CD-16-0441","article-title":"Chemotherapy-resistant human acute myeloid leukemia cells are not enriched for leukemic stem cells but require oxidative metabolism","volume":"7","author":"Farge","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.blre.2025.101323_bb1150","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.jphs.2019.10.003","article-title":"Metformin inhibits cell proliferation in SKM-1 cells via AMPK-mediated cell cycle arrest","volume":"141","author":"Zhou","year":"2019","journal-title":"J Pharmacol Sci"},{"key":"10.1016\/j.blre.2025.101323_bb1155","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/j.leukres.2015.09.016","article-title":"Metformin synergistically sensitizes FLT3-ITD-positive acute myeloid leukemia to sorafenib by promoting mTOR-mediated apoptosis and autophagy","volume":"39","author":"Wang","year":"2015","journal-title":"Leuk Res"},{"key":"10.1016\/j.blre.2025.101323_bb1160","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.ccr.2011.10.015","article-title":"Inhibition of mitochondrial translation as a therapeutic strategy for human acute myeloid leukemia","volume":"20","author":"Skrti\u0107","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.blre.2025.101323_bb1165","series-title":"STOP-LEUKEMIA: Repurposing metformin as a leukemia-preventive drug in CCUS and LR-MDS","year":"2021"},{"key":"10.1016\/j.blre.2025.101323_bb1170","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0049-3848(03)00379-7","article-title":"The mechanism of action of aspirin","volume":"110","author":"Vane","year":"2003","journal-title":"Thromb Res"},{"key":"10.1016\/j.blre.2025.101323_bb1175","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1182\/blood-2022-170761","article-title":"The effect of clonal hematopoiesis of indeterminate potential (CHIP) and aspirin on clinical outcomes in the healthy elderly: a sub-study of the aspirin in reducing events in the elderly (ASPREE) randomized controlled trial","volume":"140","author":"McQuilten","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101323_bb1180","series-title":"Aspirin in reducing events in the elderly","year":"2009"},{"key":"10.1016\/j.blre.2025.101323_bb1185","doi-asserted-by":"crossref","first-page":"6753","DOI":"10.1073\/pnas.79.22.6753","article-title":"Tubulin bound to colchicine forms polymers different from microtubules","volume":"79","author":"Andreu","year":"1982","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.blre.2025.101323_bb1190","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/0163-7258(91)90027-J","article-title":"Tubulin sulfhydryl groups as probes and targets for antimitotic and antimicrotubule agents","volume":"49","author":"Luduena","year":"1991","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.blre.2025.101323_bb1195","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nature04516","article-title":"Gout-associated uric acid crystals activate the NALP3 inflammasome","volume":"440","author":"Martinon","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.blre.2025.101323_bb1200","article-title":"Colchicine for pericarditis","volume":"2014","author":"Alabed","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.blre.2025.101323_bb1205","doi-asserted-by":"crossref","first-page":"4601","DOI":"10.1093\/eurheartj\/ehae546","article-title":"Colchicine prevents accelerated atherosclerosis in TET2-mutant clonal haematopoiesis","volume":"45","author":"Zuriaga","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.blre.2025.101323_bb1210","unstructured":"Colchicine Cardiovascular Outcomes Trial (COLCOT). 2015."},{"key":"10.1016\/j.blre.2025.101323_bb1215","series-title":"Reduction of clonal hematopoiesis mutation burden in coronary patients treated with low-dose colchicine. medRxiv","author":"Tardif","year":"2024"},{"key":"10.1016\/j.blre.2025.101323_bb1220","first-page":"101001","article-title":"CHIPing away the progression potential of CHIP: a new reality in the making","author":"Xie","year":"2022","journal-title":"Blood Rev"},{"key":"10.1016\/j.blre.2025.101323_bb1225","first-page":"1","article-title":"TP53-mediated clonal hematopoiesis confers increased risk for incident atherosclerotic disease","author":"Zekavat","year":"2023","journal-title":"Nat Cardiovasc Res"},{"key":"10.1016\/j.blre.2025.101323_bb1230","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1182\/blood.2023022260","article-title":"Jak2 V617F clonal hematopoiesis promotes arterial thrombosis via platelet activation and cross talk","volume":"143","author":"Liu","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101323_bb1235","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1681\/ASN.2021060774","article-title":"Association of clonal hematopoiesis of indeterminate potential with worse kidney function and anemia in two cohorts of patients with advanced chronic kidney disease","volume":"33","author":"Vlasschaert","year":"2022","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.blre.2025.101323_bb1240","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/s41375-021-01382-3","article-title":"Clonal myelopoiesis promotes adverse outcomes in chronic kidney disease","volume":"36","author":"Dawoud","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2025.101323_bb1245","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/s41586-022-04785-z","article-title":"The longitudinal dynamics and natural history of clonal haematopoiesis","volume":"606","author":"Fabre","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.blre.2025.101323_bb1250","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1038\/s41591-022-01883-3","article-title":"Longitudinal dynamics of clonal hematopoiesis identifies gene-specific fitness effects","volume":"28","author":"Robertson","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.blre.2025.101323_bb1255","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS7076","article-title":"Phase II trial assessing safety and preliminary efficacy of high-dose intravenous ascorbic acid in patients with <i>TET2-<\/i>mutant clonal cytopenias of undetermined significance","volume":"40","author":"Xie","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2025.101323_bb1260","doi-asserted-by":"crossref","first-page":"4296","DOI":"10.1182\/blood-2021-150398","article-title":"Reference values of human bone marrow and peripheral blood levels of 49 cytokines according to age and clonal hematopoiesis","volume":"138","author":"Ravalet","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101323_bb1265","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/joim.20080","article-title":"Clonal hematopoiesis of indeterminate potential and the risk of autoimmune diseases","volume":"297","author":"Wu","year":"2025","journal-title":"J Intern Med"},{"key":"10.1016\/j.blre.2025.101323_bb1270","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.3390\/cancers15051388","article-title":"Health-related quality of life as assessed by the EQ-5D-5L predicts outcomes of patients treated with azacitidine\u2014a prospective cohort study by the AGMT","volume":"15","author":"Pleyer","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.blre.2025.101323_bb1275","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1093\/jnci\/djab184","article-title":"Patient-reported functional outcomes in patients with chronic myeloid leukemia after stopping tyrosine kinase inhibitors","volume":"114","author":"Schoenbeck","year":"2022","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"10.1016\/j.blre.2025.101323_bb1280","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1111\/bjh.19925","article-title":"A blueprint for pursuing therapeutic interventions and early phase clinical trials in clonal haematopoiesis","volume":"206","author":"Haque","year":"2024","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2025.101323_bb1285","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1158\/1538-7445.AM2024-790","article-title":"Abstract 790: sex and race-dependent variations in the mutational landscape of clonal hematopoiesis","volume":"84","author":"Dhuri","year":"2024","journal-title":"Cancer Res"},{"key":"10.1016\/j.blre.2025.101323_bb1290","first-page":"11","article-title":"Race\/ethnicity reporting and representation in US clinical trials: a cohort study","author":"Turner","year":"2022","journal-title":"Lancet Reg Health \u2013 Am"},{"key":"10.1016\/j.blre.2025.101323_bb1295","doi-asserted-by":"crossref","first-page":"6151","DOI":"10.1182\/bloodadvances.2022008376","article-title":"Patient perspectives on testing for clonal hematopoiesis of indeterminate potential","volume":"6","author":"Sella","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2025.101323_bb1300","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/s41408-022-00703-8","article-title":"Therapy-related clonal cytopenia as a precursor to therapy-related myeloid neoplasms","volume":"12","author":"Shah","year":"2022","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.blre.2025.101323_bb1305","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101323_bb1310","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization Classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2025.101323_bb1315","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.immuni.2013.05.016","article-title":"K+ efflux is the common trigger of NLRP3 inflammasome activation by bacterial toxins and particulate matter","volume":"38","author":"Mu\u00f1oz-Planillo","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.blre.2025.101323_bb1320","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.4049\/jimmunol.147.9.2964","article-title":"IL-1-converting enzyme requires aspartic acid residues for processing of the IL-1 beta precursor at two distinct sites and does not cleave 31-kDa IL-1 alpha","volume":"147","author":"Howard","year":"1991","journal-title":"J Immunol"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X25000682?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X25000682?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T17:39:04Z","timestamp":1766079544000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X25000682"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":264,"alternative-id":["S0268960X25000682"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2025.101323","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Target practice: Opportunities for therapeutic intervention in CHIP and CCUS","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2025.101323","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101323"}}